Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15341935rdf:typepubmed:Citationlld:pubmed
pubmed-article:15341935lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:15341935lifeskim:mentionsumls-concept:C0449444lld:lifeskim
pubmed-article:15341935lifeskim:mentionsumls-concept:C0205349lld:lifeskim
pubmed-article:15341935pubmed:issue19lld:pubmed
pubmed-article:15341935pubmed:dateCreated2004-9-2lld:pubmed
pubmed-article:15341935pubmed:abstractTextOf the 42 R'-X-(p-Cl)Phe-D-Phe-Arg-Trp-NH(2) (X=CO, SO(2), PO, PS) tested at the human (h)MC1, hMC3, and hMC4 receptors (R), the most potent MC4R agonists (EC(50) of 8-20 nM) were obtained by end-capping with R'=CH(2)CHCH(2) (9), NCCH(2) (16), NH(2)COCH(2) (17), HCONHCH(2) (18), CH(3)NH (19), CH(2)CHCH(2)NH (21), 2-Th (23), PhCH(2) (30) and X=CO. These compounds possess 35-60-fold hMC4 versus hMC1Rs selectivity with urea LK-71 (19) being the most potent at hMC4R and MC4/1R selective (EC(50)=8.5 nM, MC4/1R=100). LK-75 (16) combines high potency at hMC4R and MC4/3R selectivity (EC(50)=10.5 nM, MC4/3R=290). SAR is discussed.lld:pubmed
pubmed-article:15341935pubmed:languageenglld:pubmed
pubmed-article:15341935pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15341935pubmed:citationSubsetIMlld:pubmed
pubmed-article:15341935pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15341935pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15341935pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15341935pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15341935pubmed:statusMEDLINElld:pubmed
pubmed-article:15341935pubmed:monthOctlld:pubmed
pubmed-article:15341935pubmed:issn0960-894Xlld:pubmed
pubmed-article:15341935pubmed:authorpubmed-author:HayesJ CJClld:pubmed
pubmed-article:15341935pubmed:authorpubmed-author:Cross-Doersen...lld:pubmed
pubmed-article:15341935pubmed:authorpubmed-author:KnittelJ JJJlld:pubmed
pubmed-article:15341935pubmed:authorpubmed-author:EbetinoF HFHlld:pubmed
pubmed-article:15341935pubmed:authorpubmed-author:KoikovL NLNlld:pubmed
pubmed-article:15341935pubmed:issnTypePrintlld:pubmed
pubmed-article:15341935pubmed:day4lld:pubmed
pubmed-article:15341935pubmed:volume14lld:pubmed
pubmed-article:15341935pubmed:ownerNLMlld:pubmed
pubmed-article:15341935pubmed:authorsCompleteYlld:pubmed
pubmed-article:15341935pubmed:pagination4839-42lld:pubmed
pubmed-article:15341935pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15341935pubmed:meshHeadingpubmed-meshheading:15341935...lld:pubmed
pubmed-article:15341935pubmed:meshHeadingpubmed-meshheading:15341935...lld:pubmed
pubmed-article:15341935pubmed:meshHeadingpubmed-meshheading:15341935...lld:pubmed
pubmed-article:15341935pubmed:meshHeadingpubmed-meshheading:15341935...lld:pubmed
pubmed-article:15341935pubmed:meshHeadingpubmed-meshheading:15341935...lld:pubmed
pubmed-article:15341935pubmed:year2004lld:pubmed
pubmed-article:15341935pubmed:articleTitleEnd-capping of the modified melanocortin tetrapeptide (p-Cl)Phe-D-Phe-Arg-Trp-NH2 as a route to hMC4R agonists.lld:pubmed
pubmed-article:15341935pubmed:affiliationCollege of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA.lld:pubmed
pubmed-article:15341935pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15341935pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:15341935lld:chembl